Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.

  • Zhu, Lucía
  • Retana, Diana
  • García-Gómez, Pedro
  • Álvaro-Espinosa, Laura
  • Priego, Neibla
  • Masmudi-Martín, Mariam
  • Yebra, Natalia
  • Miarka, Lauritz
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Martínez, Sonia
  • Sobrino, Cecilia
  • Ajenjo, Nuria
  • Artiga, Maria-Jesus
  • Ortega-Paino, Eva
  • Torres-Ruiz, Raúl
  • Rodríguez-Perales, Sandra
  • Soffietti, Riccardo
  • Bertero, Luca
  • Cassoni, Paola
  • Weiss, Tobias
  • Muñoz, Javier
  • Sepúlveda, Juan Manuel
  • González-León, Pedro
  • Jiménez-Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez-Núñez, Ángel
  • Hernández-Laín, Aurelio
  • Toldos, Oscar
  • Ruano, Yolanda
  • Alcázar, Lucía
  • Blasco, Guillermo
  • Fernández-Alén, José
  • Caleiras, Eduardo
  • Lafarga, Miguel
  • Megías, Diego
  • Graña-Castro, Osvaldo
  • Nör, Carolina
  • Taylor, Michael D
  • Young, Leonie S
  • Varešlija, Damir
  • Cosgrove, Nicola
  • Couch, Fergus J
  • Cussó, Lorena
  • Desco, Manuel
  • Mouron, Silvana
  • Quintela Fandino, Miguel Angel
  • Weller, Michael
  • Pastor Fernandez, Joaquin
  • Valiente, Manuel
  • Zhu, Lucía
  • Retana, Diana
  • García-Gómez, Pedro
  • Álvaro-Espinosa, Laura
  • Priego, Neibla
  • Masmudi-Martín, Mariam
  • Yebra, Natalia
  • Miarka, Lauritz
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Martínez, Sonia
  • Sobrino, Cecilia
  • Ajenjo, Nuria
  • Artiga, Maria-Jesus
  • Ortega-Paino, Eva
  • Torres-Ruiz, Raúl
  • Rodríguez-Perales, Sandra
  • Soffietti, Riccardo
  • Bertero, Luca
  • Cassoni, Paola
  • Weiss, Tobias
  • Muñoz, Javier
  • Sepúlveda, Juan Manuel
  • González-León, Pedro
  • Jiménez-Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez-Núñez, Ángel
  • Hernández-Laín, Aurelio
  • Toldos, Oscar
  • Ruano, Yolanda
  • Alcázar, Lucía
  • Blasco, Guillermo
  • Fernández-Alén, José
  • Caleiras, Eduardo
  • Lafarga, Miguel
  • Megías, Diego
  • Graña-Castro, Osvaldo
  • Nör, Carolina
  • Taylor, Michael D
  • Young, Leonie S
  • Varešlija, Damir
  • Cosgrove, Nicola
  • Couch, Fergus J
  • Cussó, Lorena
  • Desco, Manuel
  • Mouron, Silvana
  • Weller, Michael
We report a medium-throughput drug-screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood-brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug-screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity

  • Santos, Catarina P.
  • Lapi, Eleonora
  • Martínez de Villarreal, Jaime
  • Álvaro, Laura
  • Fernández-Barral, Asunción
  • Barbáchano, Antonio
  • Domínguez, Orlando
  • Laughney, Ashley M.
  • Megías, Diego
  • Muñoz Terol, Alberto
  • Real, Francisco X.
© The Author(s) 2019., Understanding urothelial stem cell biology and differentiation has been limited by the lack of methods for their unlimited propagation. Here, we establish mouse urothelial organoids that can be maintained uninterruptedly for >1 year. Organoid growth is dependent on EGF and Wnt activators. High CD49f/ITGA6 expression features a subpopulation of organoid-forming cells expressing basal markers. Upon differentiation, multilayered organoids undergo reduced proliferation, decreased cell layer number, urothelial program activation, and acquisition of barrier function. Pharmacological modulation of PPARγ and EGFR promotes differentiation. RNA sequencing highlighted genesets enriched in proliferative organoids (i.e. ribosome) and transcriptional networks involved in differentiation, including expression of Wnt ligands and Notch components. Single-cell RNA sequencing (scRNA-Seq) analysis of the organoids revealed five clusters with distinct gene expression profiles. Together with the use of γ-secretase inhibitors, scRNA-Seq confirms that Notch signaling is required for differentiation. Urothelial organoids provide a powerful tool to study cell regeneration and differentiation., This work was supported, in part, by grants from Spanish Ministry of Economy, Industry and Competitiveness (SAF2016-76377-R), CIBERONC (CB16/12/00453 and CB16/12/00273), and Fundación Científica de la Asociación Española Contra el Cáncer. CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015–0510.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of GATA4 causes ectopic pancreas in the stomach

  • Rodríguez-Seguel, Elisa
  • Villamayor Coronado, Laura
  • Arroyo, Noelia
  • Andrés, Mónica P. de
  • Real, Francisco X.
  • Martín, Franz
  • Cano González, David A.
  • Rojas, Anabel
Pancreatic heterotopia is defined as pancreatic tissue outside its normal location in the body and anatomically separated from the pancreas. In this work we have analyzed the stomach glandular epithelium of Gata4 flox/flox; Pdx1‐Cre mice (Gata4KO mice). We found that Gata4KO glandular epithelium displays an atypical morphology similar to the cornified squamous epithelium and exhibits upregulation of forestomach markers. The developing gastric units fail to form properly, and the glandular epithelial cells do not express markers of gastric gland in the absence of GATA4. Of interest, the developing glands of the Gata4KO stomach express pancreatic cell markers. Furthermore, a mass of pancreatic tissue located in the subserosa of the Gata4KO stomach is observed at adult stages. Heterotopic pancreas found in Gata4‐deficient mice contains all three pancreatic cell lineages: ductal, acinar, and endocrine. Moreover, Gata4 expression is downregulated in ectopic pancreatic tissue of some human biopsy samples., ER‐S. was supported by a ‘Juan de la Cierva’ postdoctoral fellowship from the Spanish Ministry of Economy and Competitiveness (IJCI‐2014‐19251). LV was supported by a contract from Spanish Ministry of Economy and Competitiveness (RYC‐2013‐14533). This work was supported by grants from the Spanish Ministry of Economy and Competitiveness BFU2017‐82497‐P to AR, ISCIII‐Subdirección General de Evaluación y Fomento de la Investigación co‐funded with Fondos FEDER, PI16/00175 to DAC, the Andalusian Ministry of Science and Innovation CTS‐7478 to DAC, and grant SAF2015‐70553‐R to FXR. CNIO is supported by the “Ministerio de Ciencia, Innovación y Universidades” as a Centro de Excelencia Severo Ochoa (SEV‐2015‐0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

  • Marqués, Miriam
  • Tranchant, Robin
  • Risa-Ebrí, Blanca
  • Suárez-Solís, María L.
  • Fernández, Luis C.
  • Carrillo-de-Santa-Pau, Enrique
  • Pozo, Natalia del
  • Martínez de Villarreal, Jaime
  • Meiller, Clément
  • Allory, Yves
  • Blum, Yuna
  • Pirker, Christine
  • Hegedus, Balazs
  • Barry, Simon T.
  • Carnero, Amancio
  • Berger, Walter
  • Jean, Didier
  • Real, Francisco X.
Among malignant mesotheliomas (MM), the sarcomatoid subtype is associated with higher chemoresistance and worst survival. Due to its low incidence, there has been little progress in the knowledge of the molecular mechanisms associated with sarcomatoid MM, which might help to define novel therapeutic targets. In this work, we show that loss of PTEN expression is frequent in human sarcomatoid MM and PTEN expression levels are lower in sarcomatoid MM than in the biphasic and epithelioid subtypes. Combined Pten and Trp53 deletion in mouse mesothelium led to nonepithelioid MM development. In Pten;Trp53-null mice developing MM, the Gαi2-coupled receptor subunit activated MEK/ERK and PI3K, resulting in aggressive, immune-suppressed tumors. Combined inhibition of MEK and p110β/PI3K reduced mouse tumor cell growth in vitro. Therapeutic inhibition of MEK and p110β/PI3K using selumetinib (AZD6244, ARRY-142886) and AZD8186, two drugs that are currently in clinical trials, increased the survival of Pten;Trp53-null mice without major toxicity. This drug combination effectively reduced the proliferation of primary cultures of human pleural (Pl) MM, implicating nonepithelioid histology and high vimentin, AKT1/2, and Gαi2 expression levels as predictive markers of response to combined MEK and p110β/PI3K inhibition. Our findings provide a rationale for the use of selumetinib and AZD8186 in patients with MM with sarcomatoid features. This constitutes a novel targeted therapy for a poor prognosis and frequently chemoresistant group of patients with MM, for whom therapeutic options are currently lacking., [Significance] Mesothelioma is highly aggressive; its sarcomatoid variants have worse prognosis. Building on a genetic mouse model, a novel combination therapy is uncovered that is relevant to human tumors., This work was supported, in part, by grants from Asociación Española Contra el Cáncer (F.X. Real), Spanish Ministry of Economy and Competitivity, Plan Estatal de I+D+I 2013-2016, ISCIII (FIS PI15/00045 to A. Carnero), RTICC (Instituto de Salud Carlos III, grants RD12/0036/0034 to F.X. Real and A. Carnero, respectively), and CIBERONC (CB16/12/00453 and CD16/12/00275 to F.X. Real and A. Carnero, respectively), cofunded by FEDER from Regional Development European Funds (European Union) and Inserm (Institut national de la santé et de la recherche médicale). M. Marqués was supported by a Sara Borrell Fellowship from Instituto de Salud Carlos III. CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

  • Salmón, Marina
  • Álvarez-Díaz, Ruth
  • Fustero-Torre, Coral
  • Brehey, Oksana
  • Lechuga, Carmen G.
  • Sanclemente, Manuel
  • Fernández-García, Fernando
  • López-García, Alejandra
  • Martín-Guijarro, María Carmen
  • Rodríguez-Perales, Sandra
  • Bousquet-Mur, Emily
  • Morales-Cacho, Lucía
  • Mulero, Francisca
  • Al-Shahrour, Fátima
  • Martínez, Lola
  • Domínguez, Orlando
  • Caleiras, Eduardo
  • Ortega, Sagrario
  • Guerra, Carmen
  • Musteanu, Mónica
  • Drosten, Matthias
  • Barbacid, Mariano
KRASG12C inhibitors have revolutionized the clinical management of patients with KRASG12C-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically engineered mice to compare the therapeutic efficacy and the emergence of tumor resistance between genetic ablation of mutant Kras expression and pharmacological inhibition of oncogenic KRAS activity. Whereas Kras ablation induces massive tumor regression and prevents the appearance of resistant cells in vivo, treatment of KrasG12C/Trp53-driven lung adenocarcinomas with sotorasib, a selective KRASG12C inhibitor, caused a limited antitumor response similar to that observed in the clinic, including the rapid onset of resistance. Unlike in human tumors, we did not observe mutations in components of the RAS-signaling pathways. Instead, sotorasib-resistant tumors displayed amplification of the mutant Kras allele and activation of xenobiotic metabolism pathways, suggesting that reduction of the on-target activity of KRASG12C inhibitors is the main mechanism responsible for the onset of resistance. In sum, our results suggest that resistance to KRAS inhibitors could be prevented by achieving a more robust inhibition of KRAS signaling mimicking the results obtained upon Kras ablation., This work was supported by grants from the European Research Council (ERC-GA 695566, THERACAN); the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033) (grant RTC2017-6576-1), cofunded by ERDF “A way of making Europe”; the Autonomous Community of Madrid (B2017/BMD-3884 iLung-CM), cofunded by FSE and ERDF “A way of making Europe”; the CRIS Cancer Foundation, the Scientific Foundation of the Spanish Association Against Cancer (GC166173694BARB); an ERA PerMed grant, funded by the Instituto de Salud Carlos III (AC20/00114), the Scientific Foundation of the Spanish Association Against Cancer (PERME20707BARB) and the European Union’s Horizon 2020 program (779282) to MB; and the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant RTI2018-094664-B-I00), cofunded by ERDF “A way of making Europe” to MM and MB. Additional funding included grants from the Spanish National Research and Development Plan, Instituto de Salud Carlos III, ERDF “A way of making Europe” (PI20/01837 and DTS19/00111); the Scientific Foundation of the Spanish Association Against Cancer (LABAE20049RODR) to SRP; the Instituto de Salud Carlos III (PI19/00514), cofunded by ERDF “A way of making Europe” to CG; the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant PID2020-116705RB-I00); and the Scientific Foundation of the Spanish Association Against Cancer (LABAE211678DROS) to MD. MB is a recipient of an endowed chair from the AXA Research Fund. M Salmón was supported by a predoctoral contract “Severo Ochoa” (BES-2016-079096) from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación. OB is a recipient of a fellowship from the Formación de Personal Investigador (FPI) program of the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación. FFG was supported by a Formación de Profesorado Universitario (FPU) fellowship from the Ministerio de Universidades., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR

  • Ortega-Molina, Ana
  • Deleyto-Seldas, Nerea
  • Carreras, Joaquim
  • Sanz, Alba
  • Lebrero-Fernández, Cristina
  • Menéndez, Camino
  • Vandenberg, Andrew
  • Fernández-Ruiz, Beatriz
  • Leyre Marín-Arraiza,
  • Calle Arregui, Celia de la
  • Plata-Gómez, Ana Belén
  • Caleiras, Eduardo
  • Martino, Alba de
  • Martínez-Martín, Nuria
  • Troulé, Kevin
  • Piñeiro-Yáñez, Elena
  • Nakamura, Naoya
  • Araf, Shamzah
  • Victora, Gabriel D.
  • Okosun, Jessica
  • Fitzgibbon, Jude
  • Efeyan, Alejo
The humoral immune response requires that B cells undergo a sudden anabolic shift and high cellular nutrient levels, which are required to sustain the subsequent proliferative burst. Follicular lymphoma (FL) originates from B cells that have participated in the humoral response, and 15% of FL samples harbour point-activating mutations in RRAGC, an essential activator of mTORC1 downstream of the sensing of cellular nutrients. The impact of recurrent RRAGC mutations in B cell function and lymphoma is unexplored. RRAGC mutations, targeted to the endogenous locus in mice, confer a partial insensitivity to nutrient deprivation, but strongly exacerbate B cell responses and accelerate lymphomagenesis, while creating a selective vulnerability to pharmacological inhibition of mTORC1. This moderate increase in nutrient signalling synergizes with paracrine cues from the supportive T cell microenvironment that activate B cells via the PI3K–Akt–mTORC1 axis. Hence, Rragc mutations sustain induced germinal centres and murine and human FL in the presence of decreased T cell help. Our results support a model in which activating mutations in the nutrient signalling pathway foster lymphomagenesis by corrupting a nutrient-dependent control over paracrine signals from the T cell microenvironment., Research was supported by the RETOS projects Programme of Spanish Ministry of Science, Innovation and Universities, Spanish State Research Agency, cofunded by the European Regional Development Fund (grant SAF2015-67538-R), EU-H2020 Programme (ERC-2014-STG-638891), Excellence Network Grant from MICIU/AEI (SAF2016-81975-REDT), a Ramon y Cajal Award from MICIU/AEI (RYC-2013-13546), Spanish Association Against Cancer Research Scientific Foundation Laboratory Grant, Beca de Investigación en Oncología Olivia Roddom, FERO Grant for Research in Oncology; Miguel Servet Fellowship and Grant Award (MS16/00112 and CP16/00112) and Project PI18/00816 within the Health Strategic Action from the ISCIII (to A.O.-M.), both cofunded by the European Regional Development Fund, Marcos Fernandez Fellowship from the Spanish Leukaemia and Lymphoma Foundation/Vistare Foundation (to A.O.-M.) and L’Oreal For Women in Science Award (to A.O.-M.). J.F. is a recipient of a Cancer Research UK Programme Award (15968) and J.O. is a recipient of a Cancer Research UK Clinician Scientist Fellowship (22742). N.M.-M. is a Ramon y Cajal Awardee MICIU/AEI (RYC-2016-20173). N.D.-S., C.C.A., A.B.P.-G. and K.T. are recipients of Ayudas de contratos predoctorales para la formacion de doctores from MICIU/AEI (BES-2016-077410, BES-2015-073776, BES-2017−081381, BES-2016-078082)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets

  • Hurtado, Begoña
  • Trakala, Marianna
  • Ximénez-Embún, Pilar
  • El Bakkali, Aicha
  • Partida, David
  • Sanz-Castillo, Belén
  • Álvarez-Fernández, Mónica
  • Maroto, María
  • Sánchez-Martínez, Ruth
  • Martínez, Lola
  • Redondo-Muñoz, Javier
  • García de Frutos, Pablo
  • Malumbres, Marcos
MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated in autosomal dominant thrombocytopenia. However, the connections between the cell-cycle machinery and this human disease remain unexplored. We report here that, whereas Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a consequence of aberrant activation and survival of platelets. Activation of mutant platelets was characterized by hyperstabilized pseudopods mimicking the effect of PP2A inhibition and actin polymerization defects. These aberrations were accompanied by abnormal hyperphosphorylation of multiple components of the actin cytoskeleton and were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC, or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeletal dynamics in postmitotic cells and suggest that the thrombocytopenia-associated mutation in MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity resulting in altered phosphorylation of cytoskeletal regulatory pathways., BH and RSM were supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (MINECO). MT was supported by the Foundation La Caixa. AEB was supported by the Programa de Empleo Juvenil, Comunidad de Madrid. MAF received a young investigator grant from MINECO (SAF2014-60442-JIN, cofinanced by FEDER funds). PGDF was supported by the Fundació la Marató de TV3 (projects 080121 and 20153031). JM was supported by the Ramon y Cajal Programme (MINECO; RYC-2012-10651). The laboratory of MM is supported by grants from MINECO (SAF2015-69920-R); the Programa iLUNG from the Comunidad de Madrid (B2017/BMD-3884); and Worldwide Cancer Research (15-0278). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TOP2B modulates DNA supercoiling and chromatin contacts during transcriptional induction

  • Terrón-Bautista, José
  • Bejarano-Franco, Marina
  • Del Mar Martínez-Sánchez, María
  • López-Hernández, Laura
  • Díaz-Maldonado, Héctor
  • Santiago-Gómez, Angélica
  • Kidane, Sara
  • Jaguva Vasudevan, Ananda Ayyappan
  • García-Domínguez, Mario
  • Williams, R Scott
  • Aguilera, Andrés
  • Millán-Zambrano, Gonzalo
  • Cortés-Ledesma, Felipe
Human type-II topoisomerases, TOP2A and TOP2B, resolve transcription-associated DNA supercoiling, thereby influencing gene expression programs, and have been recently linked to three-dimensional genome architecture through yet poorly understood mechanisms. Here, we investigate the regulatory roles of TOP2 paralogs using estrogen signaling, which triggers an acute transcriptional induction that involves extensive rewiring of genome organization, as a model system. Unexpectedly, we find that estrogen treatment strongly inhibits TOP2B catalytic activity-although not its binding-specifically at estrogen-responsive enhancers and promoters. This inhibition results in an accumulation of negative DNA supercoiling and promotes the formation of regulatory chromatin contacts. Estrogen-mediated inhibition of TOP2B activity depends on estrogen receptor α, a noncatalytic function of TOP2A, and, most importantly, the action of zinc finger protein associated with tyrosyl-DNA phosphodiesterase 2 and TOP2, an atypical small ubiquitin-like modifier ligase that directly inhibits TOP2 activity. This mechanism of transcriptional control, involving the fine-tuning of DNA supercoiling levels, highlights the role of DNA topoisomerases as central regulators of genome dynamics., This work is funded by the MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe” grant SAF2017-89619-R (F.C.-L.); the MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe” grant PID2020-119570RB-I00 (F.C.-L.); the MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe” grant PID2023-153302OB-I00 (F.C.-L.); the European Research Council ERC consolidator grant ERC-CoG-2014-647359 (F.C.-L.); the “la Caixa” Foundation Health Research grant HR24-00980 (F.C.-L.); the MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe” grant PID2021-127432 N (G.M.-Z.); the MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe” grant RC-CNS2022-135600 (G.M.-Z.); the Asociación Española Contra el Cáncer grant POSTD18021MILL (G.M.-Z.); the La Caixa Foundation Fellowship ID 100010434 (G.M.-Z.); the European Union Horizon 2020 Marie Skłodowska-Curie grant LCF/BQ/PR21/11840007 (G.M.-Z.); the Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía, Emergia 2021grant EMC21_00222 (G.M.-Z.); the MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe” grant PID2019-104270GB-I00/BMC (A.A.); the European Research Council ERC Advanced Grant ERC-AdG-2014-669898 (A.A.); the US National Institutes of Health intramural program, National Institute of Environmental Health Sciences (NIEHS), grant 1Z01ES102765 (R.S.W.); the Ministerio de Educación, Cultura y Deporte Predoctoral Fellowship FPU15/03656 (J.T.-B.); the Agencia Estatal de Investigación Predoctoral Fellowship SEV-2015-0510-19-1, PRE2019-090967 (M.d.M.M.-S.); and the Spanish National Cancer Center (CNIO), CNIO Friends Postdoctoral Contract (H.D.-M.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders

  • Alvaro-Espinosa, Laura
  • Marquez-Galera, Angel
  • Priego, Neibla
  • García-Calvo, Virginia
  • Perea-García, Maria
  • Hernandez-Oliver, Carolina
  • Retana, Diana
  • Sanchez, Oliva
  • Pablos-Aragoneses, Ana de
  • García-Gómez, Pedro
  • Graña-Castro, Osvaldo
  • Lapuente-Santana, Óscar
  • Serrano-Ron, Laura
  • Al-Shahrour, Fatima
  • Cayuela López, Ana
  • Peset, Isabel
  • Megías, Diego
  • Ola, Mihaela
  • Varešlija, Damir
  • Young, Leonie S.
  • Martí-Mateos, Yolanda
  • Enríquez, Jose A.
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Soengas, María S.
  • Bernhagen, Juergen
  • Antón-Fernández, Alejandro
  • Ávila, Jesús
  • Marchena, Miguel A.
  • Torres, Maximiliano
  • Castro Soubriet, Fernando de
  • Márquez-Ropero, Mar
  • Sierra, Amanda
  • López-Atalaya, José P.
  • Valiente, Manuel
  • RENACER Group
The upregulation of CD74, a chaperone involved in MHC-II antigen processing, has been mostly interpreted as indicative of antigen presentation in multiple brain disorders. However, CD74 expression has also been described in cancer cells across multiple tumor types and in the tumor microenvironment, notably in glioma. In this study, we found that the presence of CD74+ microglia/macrophages, which was induced by increased levels of interferon γ in brains affected by metastases, did not relate to its canonical pathway. Instead, the alternative function of CD74 as a cytokine receptor was pivotal. Proliferating cancer cells produced high levels of the ligand migration inhibitory factor (MIF) that bound the CD74 receptor and induced its translocation to the nucleus where it activated an NF-κB-dependent program that promoted metastatic progression. In patients, a CD74 signature was associated with more aggressive progression of brain metastatic disease, although it had no clinical correlation with the matched primary tumor. Interestingly, a pan-disease noncanonical and clinically relevant signature derived from the CD74+ myeloid population was identified that occurred in additional brain disorders, including Alzheimer's disease and multiple sclerosis. The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases and possibly other brain disorders., We thank all members of the Brain Metastasis Group for critical discussion of the manuscript; the CNIO Core Facilities for their excellent assistance; and Estefanía Sánchez-Jiménez (F. de Castro laboratory at Instituto Cajal-CSIC) and the staff at the Animal Facilities of the Instituto Cajal-CSIC for their extraordinary help with animals of the cuprizone demyelinating murine model of multiple sclerosis. Special thanks to patients and their families who donated valuable materials to RENACER and all site personnel, investigators, funders, and industry partners who supported the generation of the data within this study. Postmortem cortical brain tissue blocks from patients with multiple sclerosis and controls, as well as the associated clinical and neuropathologic data, were supplied by the Multiple Sclerosis & Parkinson’s Tissue Bank at Imperial College (London, United Kingdom), funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland, registered charity 207495. We thank J. Massagué (MSKCC) for some of the BrM cell lines. This study was funded by La Marató (201906-30-31-32; M. Valiente), MICIU (SAF2017-89643-R, SAF2014-57243-R, and SAF2015-62547-ERC to M. Valiente; PID2022-143110OB-I00 and RED2024-153909-E to F. de Castro), H2020-FETOPEN (828972; M. Valiente), Bristol Myers Squibb MRA Young Investigator Award (498103; M. Valiente), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018; 54545; M. Valiente), LAB AECC 2019 (LABAE19002VALI; M. Valiente), AECC Coordinados (PRYCO234528VALI; M. Valiente), ERC CoG (864759; M. Valiente), and ERANET-TRANSCAN-3 (TRANSCAN2021-203; M. Valiente) with funds from Instituto de Salud Carlos III/NextGenerationEU/PRTR (AC20/00114) and FC AECC (TRNSC213878VALI), CaixaResearch Health (HR23-00051; M. Valiente), MINECO-Ramón y Cajal (RYC-2013-13365; M. Valiente), MICIU/AEI/10.13039/501100011033 and ERDF (RTI2018-102260-B-I00; J.P. Lopez-Atalaya), Generalitat Valenciana (PROMETEO/2020/007; J.P. Lopez-Atalaya), Ramón Areces Foundation (CIVP20S10662 to E. Ortega-Paino/M.-J. Artiga; CIVP19S8163 to M. Valiente; and CIVP19A5917 to F. de Castro), Spanish Ministry of Science and Innovation Competitiveness MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (RTI2018-099267-B-I00 and PID2022-136698OB-I00; A. Sierra), Basque Government grants (IT1473-22; A. Sierra), Alzheimer Association award (AARG-NTF-24-1304352; A. Sierra), Breast Cancer Ireland (18239A01; L.S. Young), Research Ireland (19/FFP/6443; L.S. Young, 20/FFP-P/8597; D. Varešlija, and 23/SPP/11783; L.S. Young, D. Varešlija), Breast Cancer Now (2021 July PCC1460; L.S. Young, D. Varešlija, 2019 Aug SF1310 with the generous support of Walk the Walk; D. Varešlija), MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia, PRTR (RTI2018-099357-B-I00, PID2021-1279880B, and TED2021-131611B-I00; J.A. Enríquez), CIBERFES (CB16/10/00282; J.A. Enríquez), Foundation Leducq (17CVD04; J.A. Enríquez), MCIN/AEI/10 PID2023-147213OB-I00 (M.S. Soengas), ERC-Advanced Grant 884699 (M.S. Soengas), La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie (LCF/BQ/DI17/11620028; P. García-Gómez and LCF/BQ/DI19/11730044; A. de Pablos-Aragoneses), AECC postdoctoral fellowship (POSTD19016PRIE; N. Priego), MINECO-Severo Ochoa PhD Fellowship (BES-2017-081995; L. Alvaro-Espinosa), FPI-Severo Ochoa Fellowship PRE2018-083478 awarded by MICIU/AEI/10.13039/501100011033, and European Social Funds (FSE invierte en tu futuro; Y. Martí-Mateos). M. Valiente is an EMBO YIP member (4053). The CNIC is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S funded by MCIU/AEI/10.13039/501100011033). CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and is a Severo Ochoa Center of Excellence (SEV-2015-0510)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed